Dutasteride, a 5 Alpha Reductase Inhibitor, Could Be Associated with the Exacerbation of Inflammation in Patients with Benign Prostatic Hyperplasia

Overview

Journal Int J Urol

Specialty Urology

Date 2024 Oct 23

PMID 39441013

Authors

So Inamura

Yusuke Fukiage

Hisato Kobayashi

Manami Tsutsumiuchi

Masaya Seki

Minekatsu Taga

Masato Fukushima

Motohiro Kobayashi

Osamu Yokoyama

Naoki Terada

Affiliations

Soon will be listed here.

Abstract

Background: α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation.

Materials And Methods: Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation. Thirty-three of the patients had also been treated with dutasteride before the procedure. The degree of prostatic inflammation was quantified histologically by the ratio of high endothelial venule (HEV)-like vessels. We divided this retrospective cohort into α-1 blocker monotherapy and combination therapy (α-1 blockers + dutasteride) groups and evaluated clinical parameters of the two groups in relation to the degree of chronic prostatic inflammation. At the same time, we assessed factors exacerbating chronic prostatic inflammation.

Results: Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS total score, voiding subscore, nocturia, intermittency, weak stream, and straining were significantly lower in the combination than the monotherapy group. The duration of α-1 blockers administration was not correlated with the ratio of HEV-like vessels, while that of dutasteride was strongly correlated (correlation coefficient = 0.595; p < 0.001). Multiple regression analysis demonstrated that the duration of dutasteride administration was a key factor exacerbating the degree of chronic prostatic inflammation.

Conclusions: The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation.

Citing Articles

Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives.

Kaltsas A, Giannakas T, Stavropoulos M, Kratiras Z, Chrisofos M Diseases. 2025; 13(2).

PMID: 39997060 PMC: 11854834. DOI: 10.3390/diseases13020053.

References

Uchimura K, Rosen S . Sulfated L-selectin ligands as a therapeutic target in chronic inflammation. Trends Immunol. 2006; 27(12):559-65. DOI: 10.1016/j.it.2006.10.007. View

Xu S, Zhi H, Hou X, Jiang B . Angiotensin II modulates interleukin-1β-induced inflammatory gene expression in vascular smooth muscle cells via interfering with ERK-NF-κB crosstalk. Biochem Biophys Res Commun. 2011; 410(3):543-8. PMC: 3139968. DOI: 10.1016/j.bbrc.2011.06.021. View

Sakai Y, Kobayashi M . Lymphocyte 'homing' and chronic inflammation. Pathol Int. 2015; 65(7):344-54. DOI: 10.1111/pin.12294. View

Amory J, Wang C, Swerdloff R, Anawalt B, Matsumoto A, Bremner W . The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007; 92(5):1659-65. DOI: 10.1210/jc.2006-2203. View

Barnes P, Karin M . Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336(15):1066-71. DOI: 10.1056/NEJM199704103361506. View

Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P . Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012; 214(1):31-43. DOI: 10.1530/JOE-12-0142. View

Taga M, Hoshino H, Low S, Imamura Y, Ito H, Yokoyama O . A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma. Urol Oncol. 2015; 33(11):496.e1-9. DOI: 10.1016/j.urolonc.2015.05.026. View

Funahashi Y, Majima T, Matsukawa Y, Yamamoto T, Yoshida M, Gotoh M . Intraprostatic Reflux of Urine Induces Inflammation in a Rat. Prostate. 2016; 77(2):164-172. DOI: 10.1002/pros.23257. View

Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F . Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009; 69(16):1774-80. PMC: 2833181. DOI: 10.1002/pros.21027. View

10.

Nickel J, Roehrborn C, OLeary M, Bostwick D, Somerville M, Rittmaster R . The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2007; 54(6):1379-84. PMC: 2643127. DOI: 10.1016/j.eururo.2007.11.026. View

11.

Nickel J, OLeary M, Lepor H, Caramelli K, Thomas H, Hill L . Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol. 2011; 186(1):125-31. DOI: 10.1016/j.juro.2011.03.028. View

12.

Ito H, Wang D, Zha X, Inamura S, Seki M, Taga M . Castration increases PGE release from the bladder epithelium in male rats. Life Sci. 2017; 193:252-256. DOI: 10.1016/j.lfs.2017.10.037. View

13.

Shimizu S, Shimizu T, Tsounapi P, Higashi Y, Martin D, Nakamura K . Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLoS One. 2015; 10(8):e0133798. PMC: 4550428. DOI: 10.1371/journal.pone.0133798. View

14.

Inamura S, Shinagawa T, Hoshino H, Sakai Y, Imamura Y, Yokoyama O . Appearance of High Endothelial Venule-Like Vessels in Benign Prostatic Hyperplasia is Associated With Lower Urinary tract Symptoms. Prostate. 2017; 77(7):794-802. DOI: 10.1002/pros.23319. View

15.

Guo F, Weih D, Meier E, Weih F . Constitutive alternative NF-kappaB signaling promotes marginal zone B-cell development but disrupts the marginal sinus and induces HEV-like structures in the spleen. Blood. 2007; 110(7):2381-9. DOI: 10.1182/blood-2007-02-075143. View

16.

Carson 3rd C, Rittmaster R . The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003; 61(4 Suppl 1):2-7. DOI: 10.1016/s0090-4295(03)00045-1. View

17.

Stoolman L, Yednock T, Rosen S . Homing receptors on human and rodent lymphocytes--evidence for a conserved carbohydrate-binding specificity. Blood. 1987; 70(6):1842-50. View

18.

Zaitsu M, Tonooka A, Mikami K, Hattori M, Takeshima Y, Uekusa T . A dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia. ISRN Urol. 2013; 2013:863489. PMC: 3562692. DOI: 10.1155/2013/863489. View

19.

Han Y, Runge M, Brasier A . Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res. 1999; 84(6):695-703. DOI: 10.1161/01.res.84.6.695. View

20.

Yeh J, Hiraoka N, Petryniak B, Nakayama J, Ellies L, Rabuka D . Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase. Cell. 2001; 105(7):957-69. DOI: 10.1016/s0092-8674(01)00394-4. View